002099 Zhejiang Hisoar Pharmaceutical
- 5.36
- +0.08+1.52%
Zhejiang Hisoar Pharmaceutical News
Pinning Down Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) P/S Is Difficult Right Now
When you see that almost half of the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3.1x, Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE:002099) looks t
Health Check: How Prudently Does Zhejiang Hisoar Pharmaceutical (SZSE:002099) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when
Haixiang Pharmaceutical (002099.SZ): Currently, the hedging ratio continues to remain low, and the impact on the company's future performance will decrease
Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Form shows that the company's foreign export business is high, and the main purpose of the company hedging a certain percentage of US dollar assets is to reduce the uncertain impact of large exchange rate fluctuations and improve the company's resilience to risks. Currently, the hedging ratio continues to remain low, and the impact on the company's future performance will decrease.
Haixiang Pharmaceutical (002099.SZ): The company will not build a large-scale sales team in pharmaceutical-side sales
Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Sheet shows that the company will not build a large-scale sales team in pharmaceutical-side sales, and will mainly expand market sales by participating in collection and cooperating with other sales companies. The company successfully won the bid for the ninth batch of voglevosaccharide tablets approved last year. Supply has already begun this year, and sales markets outside of collection are also being developed simultaneously. Pantoprazole sodium enteric tablets, which passed the consistency evaluation last year, are also on sale, and this year's formulation revenue should increase by magnitude. In addition, reglinide tablets are in the supplementation phase, and a total of 5 hypoglycemic and psychotropic products are being developed
Haixiang Pharmaceutical (002099.SZ): Currently, the company's CMO/CDMO business strategic customer stock business maintains a good growth momentum
Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Form shows that the company set up a new major customer department, and the chairman personally led the team to connect with potential customers to dig deeper into strategic customer project cooperation. At the same time, it quickly responds to customer needs with the company's own advantages such as quality system, process optimization ability, and commercial large-scale production capacity, and provides strong support for customer project registration and certification, and achieve rapid commercial implementation of the project. At present, the company's CMO/CDMO business strategic customer stock business maintains a good growth momentum, and new strategic customer projects continue to advance
Haixiang Pharmaceutical (002099.SZ): As of May 10, the number of shareholders of the company was 29,008
Gelonghui, May 13 | Haixiang Pharmaceutical (002099.SZ) said on the investor interactive platform that as of May 10, the number of shareholders of the company was 29,008.
Chairman of Haixiang Pharmaceutical (002099.SZ) increased his total holdings by 696,500 shares
Haixiang Pharmaceutical (002099.SZ) issued an announcement. As of May 2, 2024, Wang Yang, the chairman of the company, had surged...
Haixiang Pharmaceutical (002099.SZ): The repurchase was completed with a cumulative cost of 151 million yuan to repurchase 31.478,500 shares
Gelonghui, May 6, 丨 Haixiang Pharmaceutical (002099.SZ) announced that as of May 1, 2024, the repurchase period has expired, and the share repurchase plan has been implemented. The actual repurchase range of this repurchase was from February 5, 2024 to April 30, 2024. The company actually repurchased 31.478,500 shares of the company's total share capital, and the highest transaction price was 6.37 yuan/share. The minimum transaction price was 3.98 yuan/share, and the total transaction amount was 151 million yuan (including transaction fees).
Haixiang Pharmaceutical (002099.SZ): Capital investment will continue to remain low in the next few years, focusing on the industrial chain and introduction of new products
Gelonghui, May 6, 丨 Haixiang Pharmaceutical (002099.SZ) said during a survey of specific subjects that the company has invested heavily in capital expenses since 2020, including environmental protection facilities, workshop renovation and construction. Environmental treatment capacity and production capacity have been gradually put in place in 2022. Capital investment will drop to a level in 2023. Capital investment will continue to remain low in the next few years, focusing on the industrial chain and introduction of new products, investing in multi-functional CDMO workshops to improve transformation efficiency, implement the principles of cost reduction and efficiency, and increase asset returns.
Haixiang Pharmaceutical (002099.SZ): The dye sector's order situation in the first quarter of this year was good, and production capacity interest rates gradually returned to normal levels
On May 6, Ge Longhui | Haixiang Pharmaceutical (002099.SZ) said when surveyed by specific subjects that the company began making flexible adjustments to the price and order status of some products last year, production capacity utilization rates and product inventory. Demand for clindamycin series and high-margin small varieties continues to be strong, and capacity utilization rates remain high. Orders from the dye sector were good in the first quarter of this year, and production capacity interest rates gradually returned to normal levels.
Haixiang Pharmaceutical (002099.SZ): Achieved revenue of 2.172 billion yuan in 2023, a year-on-year decrease of 19.68%
On April 28, Ge Longhui | Haixiang Pharmaceutical (002099.SZ) released its 2023 annual report. Operating income for the reporting period was 2.112 billion yuan, down 19.68% year on year; net profit attributable to shareholders of listed companies - 420 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 341 million yuan; basic earnings per share - 0.26 yuan.
Haixiang Pharmaceutical (002099.SZ) announced its 2023 annual results, with a net loss of 420 million yuan, changing from profit to loss
Haixiang Pharmaceutical (002099.SZ) released its 2023 annual report. The company's revenue was 2.172 billion yuan,...
Even After Rising 8.3% This Past Week, Zhejiang Hisoar Pharmaceutical (SZSE:002099) Shareholders Are Still Down 47% Over the Past Three Years
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns
Hisoar Pharma's Unit Passes German Health Regulator's Inspection
Zhejiang Hisoar Pharmaceutical's (SHE:002099) unit, Zhejiang Haixiang Sichuan Pharmaceutical, obtained good manufacturing practice certificates from Germany's health regulator for the production of it
Haixiang Pharmaceutical (002099.SZ): Subsidiary passed EU GMP certification
Gelonghui April 17 丨 Haixiang Pharmaceutical (002099.SZ) announced that its wholly-owned subsidiary Zhejiang Haixiang Chuannan Pharmaceutical Co., Ltd. has received GMP certificates for clindamycin hydrochloride APIs and clindamycin phosphate APIs issued by the Hamburg Ministry of Health and Consumer Protection (BJV), Germany. Chuannan Pharmaceutical is the company's main API production base. It once again passed the EU GMP certification in 2024, indicating that the quality system of Chuannan Pharmaceutical has always been in line with international standards, and that Chuannan Pharmaceutical's related products meet the EU market entry requirements. Chuannan Pharmaceutical's EU GMP certification this time will help the company explore and expand high-end markets in Europe and the US
Haixiang Pharmaceutical (002099.SZ) has spent 97.38 million yuan to buy back 21.8748 million shares
According to Zhitong Finance App, Haixiang Pharmaceutical (002099.SZ) announced that as of March 31, 2024, the company had repurchased a total of 21.8748 million shares through the Shenzhen Stock Exchange stock trading system, accounting for 1.3514% of the company's total share capital. The highest transaction price was 5.95 yuan/share, the minimum transaction price was 3.98 yuan/share, and the total transaction amount was 97.38 million yuan.
Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 4.1% Last Week
Key Insights The considerable ownership by retail investors in Zhejiang Hisoar Pharmaceutical indicates that they collectively have a greater say in management and business strategy A total of 25 in
Haixiang Pharmaceutical (002099.SZ): A total cost of 807.482 million yuan to buy back 1.17% of shares
Gelonghui, Feb. 29丨Haixiang Pharmaceutical (002099.SZ) announced that as of February 29, 2024, the company had repurchased a total of 18,935,998 shares through the Shenzhen Stock Exchange stock trading system, accounting for 1.1698% of the company's total share capital. The highest transaction price was 5.54 yuan/share, the minimum transaction price was 3.98 yuan/share, and the total transaction amount was RMB 807.482 million (including transaction fees).
Haixiang Pharmaceutical (002099.SZ): The number of shareholders of the company as of February 8 was 31,545
On February 20, Gelonghui | Haixiang Pharmaceutical (002099.SZ) said on the investor interactive platform that as of February 8, the number of shareholders of the company was 31,545.
Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE:002099) Shares May Have Slumped 32% But Getting In Cheap Is Still Unlikely
The Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE:002099) share price has fared very poorly over the last month, falling by a substantial 32%. Instead of being rewarded, shareholders who have alre
Analysis
Price Target
No Data
